

CONTENTS

| CHAPTER | DESCRIPTION | PAGE NO. |
|---------|--|---|
| | ABBREVIATIONS | I |
| | LIST OF TABLES | II |
| | LIST OF FIGURES | III |
| | ABSTRACT | IV |
| 1. | INTRODUCTION 1.1 <i>Staphylococcus aureus</i> 1.2 Community-Acquired MRSA (CA-MRSA) 1.3 <i>In silico</i> drug target identification through metabolic pathways analysis 1.4 Structure based drug design approaches 1.5 Justification of the work 1.6 Objectives of the study | 1 2 5 6 6 7 |
| 2. | REVIEW OF LITERATURE 2.1 <i>Staphylococcus aureus</i> 2.2 Methicillin resistant <i>Staphylococcus aureus</i> (MRSA) 2.3 Community acquired-methicillin resistant <i>Staphylococcus aureus</i> (CA-MRSA) 2.4 <i>In silico</i> drug target identification 2.5 Structure based drug design approaches in novel inhibitor designing 2.6 Fructose-bisphosphate aldolase (FBA) as a potential therapeutic drug target | 8 12 14 19 22 25 |

Contd.

| | | |
|----|--|----|
| 3. | MATERIALS AND METHOD | |
| | 3.1 Materials | 26 |
| | 3.2 Methodology | 27 |
| | 3.2.1 Putative drug target identification in CA-MRSA using metabolic pathways analysis | 27 |
| | 3.2.2 Phylogenetic analysis of candidate target Fructose-bisphosphate aldolase | 31 |
| | 3.2.3. Proteomic analysis of Fructose biphosphate aldolase in CA-MRSA | 32 |
| | 3.2.4 Homology modelling of candidate target Fructose biphosphate aldolase | 34 |
| | 3.2.5 Molecular dynamics simulation of predicted 3D structure of FBA | 35 |
| | 3.2.6 Virtual screening of fructose biphosphate aldolase as a drug target | 36 |
| | 3.2.7 <i>In silico</i> prediction of Pharmacokinetic properties | 37 |
| 4. | RESULTS AND DISCUSSION | |
| | 4.1 Putative drug target identification in CA-MRSA | 38 |
| | 4.2 Phylogenetic analysis of candidate target fructose-bisphosphate aldolase (FBA) | 62 |
| | 4.3 Proteomic analysis of Fructose biphosphate aldolase (FBA) | 67 |
| | 4.4 Homology modelling and validation of FBA | 72 |
| | 4.5 Molecular dynamics simulation of modelled structure of FBA | 77 |
| | 4.6 Virtual screening of FBA as a drug target | 80 |
| | 4.7 <i>In silico</i> prediction of pharmacokinetic properties | 89 |
| 5 | SUMMARY AND CONCLUSION | 91 |
| | REFERENCES | 94 |
| | APPENDIX-I | V |
| | PUBLISHED RESEARCH PAPERS | |